HHS pauses legal action against pharmacies making six unapproved peptides

The Department of Health and Human Services will exercise enforcement discretion to allow compounding pharmacies to offer peptides like BPC-157 and TB-500 immediately.

HHS pauses legal action against pharmacies making six unapproved peptides
Photo: NBC News

The Department of Health and Human Services is giving compounding pharmacies a temporary green light to make six peptides while the agency works on a formal rule change. In a notice filed Wednesday, the agency said it would exercise enforcement discretion, meaning it will not take legal action against compounding pharmacies that make the six unapproved peptides.

The six peptides are BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. These substances are not yet on the Food and Drug Administration list of ingredients compounding pharmacies are allowed to make, but pharmacies can start offering them now. They have been promoted online as treatments for faster healing, younger-looking skin and a longer lifespan.

The FDA said compounding pharmacies must certify the identity and purity of the compounds and must now report side effects, which was not previously mandated.

Health Secretary Robert F. Kennedy Jr. and others have argued that allowing peptides to be compounded would move people away from a growing gray market toward safer products. An HHS spokesperson, Emily Hilliard, said that under President Trump’s leadership, HHS is working to confront the risks of black-market peptides.

Dr. Peter Lurie, a former FDA official and leader of the Center for Science in the Public Interest, said the FDA was essentially turning a blind eye to widen access to drugs that have not been proven to work. Shabbir Safdar, executive director of the Partnership for Safe Medicines, said the enforcement discretion and upcoming rule change would expose Americans to untested, dangerous substances.

Key facts

  • HHS will not take legal action against pharmacies making BPC-157, epitalon, KPV, MOTS-c, semax and TB-500.
  • The six peptides are currently unapproved by the FDA.
  • Compounding pharmacies must now report side effects and certify the identity and purity of the compounds.

Three perspectives

Neutral

The Department of Health and Human Services is exercising enforcement discretion to allow compounding pharmacies to produce six unapproved peptides while a formal rule change is developed.

Positive

Health Secretary Robert F. Kennedy Jr. and others argue that allowing compounding would move people away from the gray market and toward safer products.

Negative

Critics, including Dr. Peter Lurie and Shabbir Safdar, say the move turns a blind eye to unproven drugs and exposes Americans to untested, dangerous substances.

Your week in news, every Wednesday

The biggest stories of the week for your edition, in your inbox every Wednesday morning, your time. Free, and you can unsubscribe at any time.

Choose your news coverage

Please choose and confirm your coverage.

Next storyUS loses measles elimination status as outbreaks rise

All sections

Edition